iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
Unusual Whales
IBIO-600 is a promising long-acting anti-myostatin monoclonal antibody that aims to preserve muscle and enhance body composition. It has been identified as a potential best-in-class candidate in its category.